Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval
CBSN
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for diabetes and weight loss.
The trial of the drug, orforglipron, measured its efficacy and safety in adults with Type 2 diabetes compared to a placebo. It found the pill lowered A1C, a blood level used to diagnose diabetes, by an average of 1.3% to 1.6%, across different doses, after 40 weeks.
Participants taking the highest dose also lost an average of 16 pounds.
Run 3 Space | Play Space Running Game
Traffic Jam 3D | Online Racing Game
Duck Hunt | Play Old Classic Game
Colon cancer patients saw improved survival rates after a 3-year exercise program, according to a first-of-its-kind international experiment.
WINDOW ROCK, Ariz. — Navajo Nation leaders took turns talking with the U.S. government's top health official as they hiked along a sandstone ridge overlooking their rural, high-desert town before the morning sun grew too hot.
It's an evocative idea that has long bedeviled scientists: a huge and mysterious planet is lurking in the darkness at the edge of our solar system, evading all our efforts to spot it. Some astronomers say the strange, clustered orbits of icy rocks beyond Neptune indicate that something big is out there, which they have dubbed "Planet Nine."